KR20160137528A - 크레아틴, 오메가-3 지방산 및 시티콜린의 조합 - Google Patents

크레아틴, 오메가-3 지방산 및 시티콜린의 조합 Download PDF

Info

Publication number
KR20160137528A
KR20160137528A KR1020167024567A KR20167024567A KR20160137528A KR 20160137528 A KR20160137528 A KR 20160137528A KR 1020167024567 A KR1020167024567 A KR 1020167024567A KR 20167024567 A KR20167024567 A KR 20167024567A KR 20160137528 A KR20160137528 A KR 20160137528A
Authority
KR
South Korea
Prior art keywords
creatine
omega
composition
fatty acid
further aspect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167024567A
Other languages
English (en)
Korean (ko)
Inventor
페리 렌쇼
데보라 여겔룬-토드
Original Assignee
유니버시티 오브 유타 리서치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 유타 리서치 파운데이션 filed Critical 유니버시티 오브 유타 리서치 파운데이션
Publication of KR20160137528A publication Critical patent/KR20160137528A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/187—Eicosapentaenoic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/1874—Linolenic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A23V2250/306—Creatine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020167024567A 2014-02-07 2015-02-06 크레아틴, 오메가-3 지방산 및 시티콜린의 조합 Ceased KR20160137528A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937328P 2014-02-07 2014-02-07
US61/937,328 2014-02-07
PCT/US2015/014856 WO2015120299A1 (en) 2014-02-07 2015-02-06 Combination of creatine, an omega-3 fatty acid, and citicoline

Publications (1)

Publication Number Publication Date
KR20160137528A true KR20160137528A (ko) 2016-11-30

Family

ID=53778486

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167024567A Ceased KR20160137528A (ko) 2014-02-07 2015-02-06 크레아틴, 오메가-3 지방산 및 시티콜린의 조합

Country Status (6)

Country Link
US (2) US10058552B2 (enExample)
EP (1) EP3102227A4 (enExample)
JP (1) JP2017506233A (enExample)
KR (1) KR20160137528A (enExample)
CN (1) CN106102765A (enExample)
WO (1) WO2015120299A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020085612A1 (ko) * 2018-10-23 2020-04-30 이화여자대학교 산학협력단 크레아틴 및 타우린의 혼합물을 함유하는 우울장애 및 불안장애의 치료용 약학적 조성물

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160137528A (ko) 2014-02-07 2016-11-30 유니버시티 오브 유타 리서치 파운데이션 크레아틴, 오메가-3 지방산 및 시티콜린의 조합
US11160982B2 (en) * 2017-07-05 2021-11-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating post-traumatic stress disorder in patients via renal neuromodulation
KR102269106B1 (ko) 2017-11-20 2021-06-24 주식회사 엘지화학 배터리 파워 한계 값 제어 방법
EP3563830A1 (en) 2018-05-03 2019-11-06 Commissariat à l'énergie atomique et aux énergies alternatives Micro-emulsion containing creatine fatty ester, method for preparing said micro-emulsion and uses thereof
EP3732995A1 (en) 2019-04-30 2020-11-04 Commissariat à l'énergie atomique et aux énergies alternatives Composition containing creatine fatty ester for use in medicine
EP4522144B1 (en) * 2022-05-12 2026-03-11 Alzchem Trostberg GmbH Composition comprising creatine for use in the treatment of breathing difficulties
IT202300026181A1 (it) * 2023-12-06 2025-06-06 Hope S R L Potenziata composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi quali parkinson e halzheimer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731692C (en) 1996-10-11 2001-10-11 Scarista Limited Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
DE19929995B4 (de) 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
WO2001068104A1 (en) 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
ES2341538T3 (es) * 2002-06-19 2010-06-22 N.V. Nutricia Composiciones nutricionales o farmaceuticas para aumentar la respuesta a la creatina de organismos.
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
US20050143350A1 (en) 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7776915B2 (en) 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
DE102006016227A1 (de) * 2006-04-06 2007-10-11 Degussa Gmbh Verfahren zur Herstellung von Kreatin, Kreatin-Monohydrat oder Guanidinoessigsäure
US20110274680A1 (en) * 2009-10-02 2011-11-10 Mazed Mohammad A Chemical composition and its delivery for lowering the risks of alzheimer's, cardiov ascular and type-2 diabetes diseases
WO2011143534A1 (en) 2010-05-13 2011-11-17 The Mclean Hospital Corporation Methods for the treatment of psychiatric disorders
BR112012027915A2 (pt) * 2010-05-13 2018-10-23 Nitromega Corp nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
US20130324609A1 (en) * 2010-10-08 2013-12-05 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs
KR20160137528A (ko) 2014-02-07 2016-11-30 유니버시티 오브 유타 리서치 파운데이션 크레아틴, 오메가-3 지방산 및 시티콜린의 조합

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020085612A1 (ko) * 2018-10-23 2020-04-30 이화여자대학교 산학협력단 크레아틴 및 타우린의 혼합물을 함유하는 우울장애 및 불안장애의 치료용 약학적 조성물

Also Published As

Publication number Publication date
US20180263983A1 (en) 2018-09-20
US10058552B2 (en) 2018-08-28
JP2017506233A (ja) 2017-03-02
EP3102227A4 (en) 2017-09-27
WO2015120299A1 (en) 2015-08-13
US20170165264A1 (en) 2017-06-15
US10265317B2 (en) 2019-04-23
CN106102765A (zh) 2016-11-09
EP3102227A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
US10265317B2 (en) Combination of creatine, an omega-3 fatty acid, and citicoline
Chitimus et al. Melatonin’s impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease
AU2022283769B2 (en) Neuroactive steroids, compositions, and uses thereof
US12558324B2 (en) Application of R-ketamine and salt thereof as pharmaceuticals
US8354438B2 (en) Neurological functions
US11337945B2 (en) C5 ketone compositions, and related methods, for therapeutic and performance supplementation
Gareri et al. The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives
Sakellaris et al. Prevention of traumatic headache, dizziness and fatigue with creatine administration. A pilot study
Brennan et al. A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression
JP2021535159A (ja) スパイン形成のためのファシン結合化合物
Russo et al. COVID-19 and first manic episodes: a systematic review
EP2624821B1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
JP6951449B2 (ja) （＋）−２−ボルネオールの、スフィンゴシンキナーゼ−１および／又はｂｄｎｆの発現の上方制御を促進する医薬の調製における使用
US20090275597A1 (en) Methods of treating cns disorders
WO2003013514A1 (en) Improving neurological functions
RU2477722C1 (ru) Способ получения литиевой соли коменовой кислоты и применение ее как антиоксидантного стресс- и нейропротекторного средства
JP2020503242A (ja) Ｓａｉｃａｒの蓄積を減少させる化合物及び使用
CN116036076A (zh) 氨基酸锂在制备用于治疗躁狂类精神疾病的药物中的应用
US20130324609A1 (en) Depression disorder therapeutics with creatine analogs
Sakellaris et al. Outcome of traumatic dysarthria and lingual problems of understanding with creatine administration. an open label randomized pilot study
CN114867474A (zh) 中枢神经系统病症的联合治疗
Suspene et al. Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review
JP2025121388A (ja) 認知機能を改善するための薬物を調製するための組成物の使用
Jadah et al. When Genes Misfire: ARV1 and the Unseen Battle Against Pediatric Epileptic Encephalopathy
Marazziti et al. Effectiveness of risperidone in psychogenic stiff neck

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160906

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200204

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211112

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220530

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211112

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I